Brian Hilberdink

Brian Hilberdink is an accomplished global executive with over 25 years of leadership experience in the pharmaceutical industry. Renowned for driving impactful results and fostering cultures of accountability and engagement, he consistently enhances organizational performance.

In February 2025, Hilberdink joined Boehringer Ingelheim as President of U.S. Human Pharma. In this role, he oversees several business units across multiple therapeutic areas, including cardiometabolic and renal diseases, obesity, pulmonary fibrosis (ILD), and oncology. His appointment comes at a pivotal time for the company as it prepares to launch multiple innovative products from its pipeline.

Previously, Hilberdink served as Executive Vice President at LEO Pharma, where he led the North American Region and served as President of the U.S. affiliate. Under his leadership, the U.S. business was transformed into the company’s primary global growth engine ahead of an anticipated IPO.

Earlier in his career, Hilberdink held several senior-level positions at Novo Nordisk, where he worked across multiple geographies. He was recognized for developing and executing innovative go-to-market strategies, resulting in the successful launch of multiple blockbuster therapies in the areas of obesity and diabetes.